We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that its heart-failure treatment Farxiga has been approved in the U.S. by the Food and Drug Administration.
The U.K. pharmaceutical giant said Farxiga has been approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction with and without type-2 diabetes.
The decision follows the priority review designation granted by the FDA earlier in 2020 and the fast-track designation granted September 2019.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
May 06, 2020 02:27 ET (06:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
